A Duke University startup dedicated to transforming the lives of patients with Lysosomal Storage Diseases (LSDs) through superior delivery and disruptive economics.
LSDs affect 1 in 5,000 live births. While treatments exist, they often fail to reach critical tissues like the heart and skeletal muscle, leaving patients to face progressive disability.
Our IGF2 platform targets receptors that current treatments miss, reaching the heart and muscle with 7-10x higher efficiency.
We leverage manufacturing processes that reduce production costs by 80–90%, making therapy more accessible.
Our technology scales from classical enzyme therapy to the next frontier of AAV-mediated gene therapy.